Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLDN18.2-CD137
- Development stage
- Preclinical
- Lead developer
- NovaRock Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CLDN18.2-CD137 is a bispecific antibody (BsAb) being developed by NovaRock Biotherapeutics for the treatment of solid tumors, including gastric and pancreatic cancers. The molecule is designed to simultaneously bind to Claudin 18.2 (CLDN18.2), a protein highly expressed in several gastrointestinal cancers, and CD137 (4-1BB), a potent costimulatory receptor found on activated T cells and natural killer (NK) cells. By targeting both, the drug aims to concentrate CD137-mediated immune activation within the tumor microenvironment, thereby enhancing anti-tumor efficacy while reducing the systemic side effects typically associated with traditional CD137 agonists. The program is currently in the IND-enabling stage of development.
- Other names
- CLDN18.2/CD137
02
Targets
Claudin 18.2TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on CLDN18.2-CD137.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLDN18.2-CD137.